Metagenomics and probiotics  by Gueimonde, M. & Collado, M.C.
Metagenomics and probiotics
M. Gueimonde1 and M. C. Collado2
1) Instituto de Productos La´cteos de Asturias (IPLA), Consejo Superior de Investigaciones Cientı´ﬁcas (CSIC), Asturias, Spain and 2) Instituto de Agroquı´mica
y Tecnologı´a de Alimentos (IATA), Consejo Superior de Investigaciones Cientı´ﬁcas (CSIC), Valencia, Spain
Abstract
The development of extensive sequencing methods has allowed metagenomic studies on the human gut microbiome to be carried out.
This has tremendously increased our knowledge on gut microbiota composition and activity, allowing microbiota aberrations related to
different diseases to be identiﬁed. These aberrations constitute targets for the development of probiotics directed to correct them.
Probiotics are extensively used to modulate gut microbiota. Nevertheless, metagenomic studies on the effects of probiotics are still very
scarce. In the near future, the use of metagenomics promises to expand our understanding of probiotic action.
Keywords: Probiotics, Metagenomics, Microbiota, Microbiome
Original Submission: 23 November 2011; Accepted: 20 March 2012
Editors: A. Moya, Rafael Canto´n, and D. Raoult
Clin Microbiol Infect 2012; 18 (Suppl. 4): 32–34
Corresponding author: M. Gueimonde, IPLA-CSIC, Ctra. Inﬁesto
s/n, 33300 Villaviciosa, Asturias, Spain
E-mail: mgueimonde@ipla.csic.es
Human intestinal microbiota
The human gastrointestinal tract (GIT) harbours a very com-
plex and dynamic microbial community which is speciﬁc for
each person depending on environmental and genetic factors
[1]. Each individual harbours about 1.5 kg of bacteria that
can account for up to 60% of faecal weight. This microbial
community, containing hundreds of different species, varies
along the GIT, the stomach being sparsely populated (103–
104 CFU/g contents) whilst the colon is heavily populated
(1011–1012 CFU/g contents).
This gut microbiota plays an important role in human
health, not only due to its participation in the digestion pro-
cess, but also for its critical function in the development of
the gut and the immune system [2,3]. A role of the GIT mic-
robiota on the regulation of absorption and storage of lipids
has also been demonstrated, constituting a promising area of
research on the ﬁght against obesity [4]. Moreover, recent
studies suggest that speciﬁc aberrations in gut microbiota
composition are associated with different diseases [5]. The
rationale for modulating the gut microbiota by means of
probiotics derives from this demonstration on the impor-
tance of gut microbiota on host health.
Probiotics
Probiotics are deﬁned as ‘live microorganisms which when
administered in adequate amounts confer a beneﬁt on the
host’ [6]. According to this deﬁnition the term probiotic
refers to strains for which speciﬁc beneﬁcial effects have
been scientiﬁcally demonstrated. Therefore, the properties
and characteristics of each individual strain should be well
deﬁned and the effect of each strain demonstrated in a case
by case manner. Some of the beneﬁcial effects attributed to
speciﬁc probiotic strains are supported by good scientiﬁc
evidence from human intervention studies whilst other
effects, although promising, are merely hypothetical at the
moment [7].
Different microorganisms have been used as probiotics,
among the most frequently used being Lactobacillus and Biﬁdo-
bacterium. Most of the currently used strains have been iso-
lated from the intestinal microbiota of healthy humans,
which establishes a strong relationship between probiotics
and gut microbiota research. In addition, most of their
effects on human health are thought to be mediated through
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modulation of the intestinal microbiota composition and/or
activity.
Metagenomics in microbiome and
probiotics research
Until the last decade our knowledge on microbiota composi-
tion and development was largely based on the use of tradi-
tional culture-based methods. The use of culturing has
provided interesting data but unfortunately also a very biased
view of the gut microbiota composition. The recent develop-
ment of molecular culture-independent techniques has dem-
onstrated that only a minority of the members of the
microbiota are culturable, and therefore most of the
microbes present in the gut had escaped scientiﬁc scrutiny
until recently.
During the last 20 years several qualitative and quantita-
tive culture-independent techniques, mostly based on the
PCR and DNA hybridization, have been developed and
applied to microbiota assessment. More recently, the devel-
opment of fast and low cost DNA sequencing methods has
allowed these modern techniques to be applied to the study
of microbial communities directly in their environment with-
out the need for species cultivation and isolation (so-called
metagenomics) to characterize the human gut microbiome
[8,9]. These techniques, based on extensive sequencing of
DNA, have increased enormously our knowledge on microb-
iome composition and activity. The study of entire microbial
communities using metagenomic approaches has revealed a
much greater diversity than was previously thought to exist
and has helped to determine the community structure of
several previously unknown ecosystems. The development of
these techniques is also contributing enormously to many
different aspects of probiotics research (Fig. 1).
Over 3 million genes from the intestinal microbiome have
been sequenced so far [9] and the existence of different
human enterotypes has been identiﬁed [10]. The process of
microbiota establishment in the newborn has been charac-
terized in detail by using metagenomics [11] and the effect of
diet has also been assessed [12]. Determining the microbi-
ome of healthy compared with diseased individuals has
allowed aberrations related to different human diseases to
be identiﬁed, such as inﬂammatory disease or obesity [4,9].
In the probiotics ﬁeld these aberrations constitute clear tar-
gets for the future development of products directed to
counteract them.
Similarly, several projects have sequenced genomes of
probiotics and intestinal commensal bacteria. This is allowing
an understanding of the role of microbiota and probiotics in
inﬂuencing human health. Genomic data on important intesti-
nal microbiota members, such as Biﬁdobacterium or Bactero-
ides, have shown the genetic basis of the adaptation of these
microorganisms to the intestinal environment. Genome
sequencing of speciﬁc probiotic strains has also provided
data on interesting properties of probiotics, including mecha-
nisms of adhesion to the gut mucosa or interaction with the
immune system, among others [13].
Challenges in microbiome and probiotics
research
One of the major challenges in this ﬁeld is to deﬁne the
composition and activity of the healthy normal microbiota.
Recent studies have shown differences in the microbiota
composition of healthy subjects from different geographical
locations [14], underlining the difﬁculties in deﬁning the nor-
mal microbiota at microbial species level. However, metage-
nomic studies have provided new insight, indicating that the
normal microbiota may be better deﬁned at functional than
at phylogenetic level. Thus, in order to understand the func-
tional shift and restoration of the healthy condition induced
by the probiotic, metagenomic studies should go beyond the
taxonomic composition as inferred by the 16S rRNA gene
and try to characterize the full genetic repertoire of the
community [9]. Once the healthy human gut microbiota is
deﬁned the next step will be to develop intervention strate-
gies targeted to modulating aberrant microbiota states
towards healthy composition and activity. In this regard, pro-
biotics constitute a promising option to achieve this aim.
A deeper understanding of the microbiome-modulating abili-
ties of speciﬁc probiotic strains is thus needed. So far, the
metagenomic data available from human intervention studies
with probiotics are very limited. Nevertheless, a plethora of
such data is expected in the near future and some studies
FIG. 1. Some contributions of metagenomics to the ﬁeld of probiotics.
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are already under way. Incorporating such data with studies
on host gene response to changes in microbiota, and pro-
biotic administration, will allow us to understand microbe–
microbe and host–microbe interactions and therefore how
the gut microbiota affects our well-being and, in broader
terms, our physiology.
It is important to underline that, as with any other tech-
nique, metagenomics may be subject to certain biases. Sam-
pling, storage of samples and DNA extraction methods are
likely to have an inﬂuence on the results obtained, and
therefore comparative studies in this ﬁeld are very welcome.
When phylogenetic studies are carried out the ampliﬁcation
of the 16S rRNA gene, or a region of it, is often needed. It
has been shown that this PCR ampliﬁcation step is critical
and the use of different primers may lead to a different rep-
resentation of certain bacterial groups [15]. In this regard, it
is surprising that in numerous metagenomic studies
sequences from biﬁdobacteria are either absent or present
at low levels, whilst using other methods these microorgan-
isms appear to be present at relatively high levels in the
same samples [1]. This example points out the need for fur-
ther ﬁne tuning of metagenomic techniques in order to avoid
methodological biases that may have a profound effect on
the results obtained. Another important point that should
always be considered before running metagenomic studies is
the sequencing depth, as it correlates directly with the cost,
as well as the management and analysis of the massive
amount of data generated, which requires the availability of
storage capability and bioinformatics tools.
Conclusions
It has been known for a long time that alterations in gut mic-
robiota are related to certain diseases, e.g. antibiotic-
associated diarrhoea. However, until recently the beneﬁcial
effects of the microbiota on health have been less widely
known. These beneﬁts associated with an appropriate micro-
biota composition and activity constitute the ‘proof of con-
cept’ for probiotics. Beneﬁcial intestinal microbes constitute
the main source for isolation of potential probiotic strains tar-
geted at modulating the human microbiome to restore health.
The normal healthy microbiota cannot be easily deﬁned
but the development of metagenomics is rapidly extending
our understanding of the role the microbiota plays in our
health. This is allowing new potential areas of application of
probiotics to be identiﬁed, including body sites other than
the gut, as well as development of an understanding of
mechanisms of action.
Combination of genome, microbiome and host-response
data promises to bring probiotic research to a new level, in
which scientiﬁc criteria for selection of effective strains for
different conditions will be available worldwide for the scien-
tiﬁc community to the beneﬁt of consumers.
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